Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Matthew Maurer"'
Autor:
Erin Honan, Melissa K. Accordino, Ruby Wu, Kathleen Fenn, Tizita Z. Zeleke, Kevin Kalinsky, Cody Chiuzan, Qingfei Pan, Dawn L. Hershman, Jose Silva, Jiyang Yu, Matthew Maurer, Meghna S. Trivedi, Katherin D Crew, Maika Onishi, Sean A. Kelly
Publikováno v:
Cancer Research. 80:P1-19
Background:HDAC6, a cytoplasmic histone deacetylase, impacts cell viability by influencing protein metabolism, microtubule dynamics, and chaperone function. ACY-1215 is an orally active, selective HDAC6 inhibitor. Preclinical studies have demonstrate
Autor:
Katherine D. Crew, DL Hershman, Sohyae Lee, Kevin Kalinsky, Matthew Maurer, Trivedi, Melissa K. Accordino, Kathleen Fenn
Publikováno v:
Cancer Research. 79:P6-18
Background: The epidermal growth factor receptor (EGFR) is frequently overexpressed in triple negative breast cancer (TNBC). However, EGFR inhibitors have not shown efficacy as monotherapy in TNBC. One strategy for overcoming resistance to EGFR inhib
Autor:
Tizita Z. Zeleke, Matthew Maurer, Meghna S. Trivedi, Ruby Wu, Katherine D. Crew, Mariano J. Alvarez, Pei Ling Chia, Sean A. Kelly, Qingfei Pan, Dawn L. Hershman, Min Yang, Andrea Califano, Jiyang Yu, Partha Mukhopadhyay, Melissa Kate Accordino, Maika Onishi, Cody Chiuzan, Erin Honan, Kathleen Fenn, Jose Silva, Simon Jones, Kevin Kalinsky
Publikováno v:
Cancer Research. 81:645-645
Despite the anticancer activity of pan-histone deacetylase (HDAC) inhibitors, their clinical use has been limited due to toxicity. However, the development of more specific inhibitors that selectively inhibit individual HDACs is emerging as a novel a
Autor:
SJ Isakoff, RL Moroose, Joyce A. O'Shaughnessy, Linda T. Vahdat, Wells A. Messersmith, Michael J. Guarino, William A. Wegener, Ayca Gucalp, Allyson J. Ocean, IA Mayer, Francois Wilhelm, David M. Goldenberg, Aditya Bardia, Jordan Berlin, Robert M. Sharkey, Jennifer R. Diamond, Jenny C. Chang, Matthew Maurer, Sajeve Samuel Thomas, Pius Maliakal, Andres Forero, Kevin Kalinsky, Alexander Starodub, TA Traina
Publikováno v:
Cancer Research. 76:PD3-06
Background: Triple-negative breast cancer (TNBC) comprises about 15% of all breast cancer types, and has a particularly aggressive course. Following first-line therapy, the median PFS is 90% of TNBC, as measured by IHC, we conducted a trial to evalua
Autor:
Sheldon Feldman, Matthew Maurer, S Refice, Bret Taback, Kevin Kalinsky, Dawn L. Hershman, Katherine D. Crew, Hanina Hibshoosh, Eileen P. Connolly, Tian Zheng
Publikováno v:
Cancer Research. 75:P6-12
Background: Laboratory and population studies demonstrate that metformin offers a beneficial breast cancer (BC) effect. In vitro, metformin has been shown to induce cycle cycle arrest. In a pre-surgical metformin trial of overweight/obese, multi-ethn
Autor:
Ingrid A. Mayer, Ian E. Krop, Joanne Lager, Sara M. Tolaney, A DeCillis, EP Winer, H. A. Burris, E Gartner, R Ruiz-Soto, Cristina Saura, Matthew Maurer
Publikováno v:
Cancer Research. 71:P1-17
BACKGROUND: Most HER2+ MBC patients (pts) treated with a combination of T+P progress within 1 year. Activation of downstream pathways through either deficiency in PTEN or mutations in the PI3K pathway has been implicated in the development of resista
Autor:
Xiaomei Wang, Mervi Laakso, Y. Rebecca Chin, Carlos Cordon-Cardo, Benjamin D. Hopkins, Hanina Hibshoosh, Susan Koujak, Lao H. Saal, Mary Beth Terry, Jorma Isola, Tao Su, Jiaping Wu, Da In Kim, Jennifer S. Ferris, Yuli Xie, Jean J. Zhao, Jennifer S. Yu, Bhaskar Dutta, Albert Rojtman, Gordon B. Mills, Sofia K. Gruvberger-Saal, Christina R. Barkley, Vundavalli V. Murty, Subhadra V. Nandula, Lorenzo Memeo, Alex Toker, Tulio Matos, Matthew Maurer, Ramon Parsons
Publikováno v:
Cancer Research. 69:6299-6306
Lesions of ERBB2, PTEN, and PIK3CA activate the phosphatidylinositol 3-kinase (PI3K) pathway during cancer development by increasing levels of phosphatidylinositol-3,4,5-triphosphate (PIP3). 3-Phosphoinositide-dependent kinase 1 (PDK1) is the first n
Autor:
Andrea Califano, Ruth Rodriguez-Barrueco, Kevin Kalinsky, Matthew Maurer, Jennifer S. Yu, Jose M. Silva
Publikováno v:
Cancer Research. 76:PD3-03
Although HER2+ tumors are commonly considered as a single entity there is increasing evidence indicating that important intrinsic differences associated to hormone receptor status (HR) exist. Indeed, while HR+/HER2+ patients benefit from anti-hormona
Autor:
Prabhjot Mundi, Katherine D. Crew, Eileen P. Connolly, Dawn L. Hershman, Kevin Kalinsky, Matthew Maurer, Andrea Calfiano, Hanina Hibshoosh
Publikováno v:
Cancer Research. 75:OT1-1
Background: Neoadjuvant chemotherapy (NACT) is standard of care in operable breast cancer (BC). There are no therapies that have demonstrated benefit in patients who failed to achieve a pathologic complete response (pCR). There remains an unmet need
Autor:
Ellen Chuang, Kevin Kalinsky, Shing Lee, Andrea Califano, Katherine D. Crew, Dawn L. Hershman, Dow-Chung Chi, Della F. Makower, Jose M. Silva, Matthew Maurer, Amy Tiersten
Publikováno v:
Cancer Research. 75:OT1-1
Background Integrated analysis of whole genome RNAi screening with computationally reverse engineered interactome models identified IL6/JAK/STAT as a master regulator pathway essential for growth of ErbB2/HER2 positive breast cancer. Ruxolitinib (R),